The impact of moderate and severe asthma exacerbations on quality of life: a post hoc analysis of randomised controlled trial data

Andrew Briggs 1, Shuaib Nasser 2, Eva Hammerby 3*, Sarah Buchs 3 and J. Christian Virchow 4

Abstract

Background: This paper reports the duration of moderate and severe exacerbations in patients with house dust mite induced allergic asthma and the impact on patients' quality of life.

Methods: Post-hoc analyses were conducted using data collected during a phase III multi-national trial (MT-04) that investigated time to moderate or severe asthma exacerbation among 485 patients during withdrawal from inhaled corticosteroids. Patient diaries were analysed to ascertain duration of exacerbations. The impact on patients' quality of life was measured by calculating utilities for five health states using the EuroQol-5 Dimension (EQ-5D-3L) and Asthma Quality of Life Questionnaire (AQL-5D). A regression analysis predicted the disutility of moving from 'well controlled asthma' to the other four health states: 'partially controlled asthma', 'uncontrolled asthma', 'moderate exacerbation' and 'severe exacerbation'.

Results: Two hundred four patients experienced exacerbations. Moderate and severe exacerbations involved statistically significant reductions in lung function compared to the constant peak expiratory flow observed for patients without exacerbations. Lung function decline occurred for 28 days, decreasing approximately 14 days before an exacerbation followed by a return to baseline over 14 days. Asthma symptoms, the use of short-acting β2-agonists, and frequency of nocturnal awakening all increased, starting 10–14 days before an exacerbation, and returned to baseline within 10–28 days following exacerbations. Compared to 'well controlled asthma', the disutility of having a 'moderate exacerbation' ranged from $-0.0834$ to $-0.0921$ (EQ-5D-3L) and from $-0.114$ to $-0.121$ (AQL-5D); and of having a 'severe exacerbation' from $-0.115$ to $-0.163$ (EQ-5D-3L) and from $-0.153$ to $-0.217$ (AQL-5D), depending on the length of the observation period.

Conclusions: The impact of moderate and severe exacerbations in house dust mite induced allergic asthma extends 14 days before and 28 days after the peak exacerbation event. The impact of exacerbations on patients' health-related quality of life (HRQoL) continues long after their occurrence.

Keywords: Allergic asthma, Asthma, House dust mite allergic asthma, Asthma exacerbation, Exacerbation, Quality of life, Utility

Background section

Allergic asthma (AA) is the most common type of asthma [1]. It is a chronic global health problem accounting for substantial morbidity and health-care expenditures [2, 3]. The total annual cost of asthma in Europe is estimated to be €19.3 billion [4]. Moderate and severe exacerbations significantly increase asthma-related and total health-care costs [5].

House dust mite (HDM) induced AA (HDM AA) is a hypersensitivity reaction to inhaled airborne HDM allergens. HDM is the most prevalent indoor allergen associated with asthma [6, 7], with 47.7% of European adults with asthma sensitised to HDM allergens [8]. HDM AA adversely impact patients' health-related quality of life.
Exacerbations are serious complications of asthma, characterised by episodes of acute deterioration of progressively worsening bronchial obstruction, which can lead to shortness of breath, coughing, wheezing and/or chest tightness [13]. Exacerbations may subside spontaneously or in response to treatment, but often require systemic corticosteroids for 5 to 7 days [11]. Severe exacerbations may require hospitalisation and can be life-threatening [11, 14], and while they are more common with poorly controlled asthma [15], they can also occur in mild [16, 17] or well-controlled asthma [18].

The Global Initiative for Asthma (GINA) outlines the characteristics that determine whether patients are classified as having ‘well controlled’, ‘partly controlled’ or ‘uncontrolled’ asthma: daytime symptoms, limitations of activities, nocturnal symptoms/awakening, need for reliever/rescue treatment, lung function and exacerbations [19]. GINA recommends [19] that a patient’s level of asthma control (their GINA “control status”) and current treatment should determine what pharmacologic treatment should be selected.

The only disease-modifying treatment for allergic disease including AA is allergy immunotherapy (AIT). AIT has been shown to limit disease progression in children with HDM allergy by preventing the development of new allergic sensitisations [20]. HDM sublingual immunotherapy (SLIT) is recommended in the GINA guidelines as a treatment for uncontrolled asthma with exacerbations despite inhaled corticosteroids (ICS) provided the FEV₁ is > 70% predicted [21].

The multinational European MT-04 trial was the first trial to assess asthma exacerbations using AIT [22]. Although exacerbations are a key outcome in asthma research, trials often do not distinguish between moderate and severe exacerbations [23]. Lloyd [12] investigated the impact of exacerbations on HRQoL by different severity grades of exacerbations, defined by what treatment was required to treat the exacerbation. MT-04 was the first study to include an assessment of both moderate and severe exacerbations using the following definitions: the ATS/ERS definition of a moderate exacerbation translated into a more measurable format suitable for a clinical trial [24]; and the ATS/ERS description for severe exacerbations [13] (Table 1).

The current paper reports post-hoc analyses of the MT-04 trial data that investigated the duration of both moderate and severe exacerbations and their impact on patients’ HRQoL, measured through utility. This is of relevance as only limited data are available about exacerbation duration, with one patient survey suggesting that this could be more than 21 days [23].

### Methods

#### Study subjects

The MT-04 trial methods have been described in detail elsewhere [22]. The relevant independent ethics committees and institutional review boards approved the trial protocol and amendments in each of the 13 countries, and the trial followed the principles of the Helsinki Declaration.

#### Study design

This paper reports two post-hoc analyses of the European MT-04 phase III multi-national, randomised, double-blind, placebo-controlled trial. The primary endpoint of MT-04 was time to first moderate or severe asthma exacerbation during the period of ICS reduction and withdrawal. The first post-hoc analysis investigated the duration of exacerbations through an analysis of patients’ electronic diaries (e-diaries). The second analysis derived utilities (patients’ preferences) for five mutually exclusive asthma health states (well controlled, partially controlled, uncontrolled, moderate and severe exacerbation) derived from the trial data through a stepwise approach in order to measure the impact of asthma control and exacerbations on patients’ HRQoL.

#### Methods

The MT-04 trial was divided into three periods (see Fig. 1). In period 1 (5 to 7 weeks), patients were screened and switched from their regular ICS asthma controller to budesonide and SABA. Following randomisation to either SQ® HDM SLIT-tablet (6 SQ-HDM or 12 SQ-HDM) or placebo, patients continued with treatment during period 2 (7–12 months). In period 3, treatment with SQ® HDM SLIT-tablet and placebo continued but patients’ daily ICS was reduced by 50% for 3 months (period 3A) and was then withdrawn for the next 3 months (period 3B).

The following data, relevant for the present post-hoc analysis, were collected:

- E-diaries, capturing asthma symptoms (measured using the Daily Symptom Score), SABA use (puffs per day), nocturnal awakenings (times per night) and lung function (PEF), were completed twice daily, starting during the final 4 weeks of period 2 (defined as period 2B) and continuing throughout period 3 (3A and 3B).
- Asthma Control Questionnaire (ACQ-7) data, assessing patients’ asthma control on a 7-point scale (0 = no impairment, 6 = maximum impairment) across 7 domains (the top scoring 5 symptoms, FEV₁% predicted value and daily SABA use), were collected at 11 scheduled visits during periods 2 and 3.
The Asthma Quality of Life Questionnaire (AQLQ) measuring the functional problems (in physical, emotional, social and occupational domains) that are most troublesome to adults with AA was completed by patients once during the middle of period 2 and five times throughout period 3 (including at unscheduled visits due to exacerbations) (Fig. 1). The AQLQ uses a 7-point polytomous response scale ranging from 1 (severely impaired) to 7 (not impaired at all) across the four domains.

**Analysis**

The post-hoc analyses investigated the duration of moderate and severe exacerbations through patient diary data, and the impact of exacerbations on patients’ HRQoL by using AQLQ data to derive utilities.

**Duration of exacerbations**

E-diary data was used to visualise the duration of exacerbations. Baseline-adjusted mean scores for e-diary data for the 4 weeks before and after the patients’ first exacerbation were compared to the final 8 weeks of data for patients who did not experience exacerbations. For subjects who did not exacerbate, the last 8 weeks of e-diary data were used as this period (3B, ICS withdrawal) is when many exacerbations occur and was expected to provide the most appropriate control group.

---

### Table 1 Definitions of moderate and severe exacerbations used in the MT-04 trial

| Criteria defining moderate exacerbations [24] | Criteria defining severe exacerbations [13] |
|-----------------------------------------------|--------------------------------------------|
| 1 or more of the following criteria and must also result in a temporary change in treatment: | 1 or more of the following criteria: |
| ● Nocturnal awakening(s) due to asthma requiring SABA use for at least 2 consecutive nights or an increase of at least 0.75 points in daily symptom score from baseline value on at least 2 consecutive days; | ● A requirement for systemic corticosteroids for the treatment of asthma symptoms for at least 3 days; |
| ● An increase from baseline in SABA use on at least 2 consecutive days (a minimum increase of 4 puffs per day); | ● An emergency department visit due to asthma requiring systemic corticosteroids, or a hospitalization for more than 12 h due to asthma. |
| ● A 20% or more decrease in peak expiratory flow from baseline on at least 2 consecutive mornings or evenings or a 20% or more decrease in FEV1 from baseline; | |
| ● A visit to the emergency department or an unscheduled visit to the trial site for asthma treatment not requiring systemic corticosteroids. | |

**FEV1** Forced Expiratory Volume in 1 s, **SABA** Short-acting β2-agonists

---

**Fig. 1** MT-04 trial design
Deriving utilities
Utilities at each visit for 5 mutually exclusive asthma health states were derived by mapping AQLQ data (Fig. 2) using the definition of asthma exacerbations used in the trial (Table 1) and GINA asthma control status. AQLQ data for each patient was categorized into the health states in a hierarchical approach at each scheduled or unscheduled visit. If patients had an exacerbation within a given number of days after a visit, the AQLQ data was categorized as a moderate or severe exacerbation at that visit. All remaining AQLQ data points were grouped according to the GINA asthma control status of the patient. Categorisation of control status was done by mapping ACQ data to the GINA asthma control status categories (Fig. 2) (well controlled, partially controlled and uncontrolled) using a published algorithm [25]. Observation periods of 7, 14, 21 and 28 days from an asthma exacerbation were used to include AQLQ data, in order to explore how long the impact of an asthma exacerbation on patients’ utility lasts.

Utility values were obtained in two ways: by mapping to the Asthma Quality of Life Questionnaire (AQL-5D) from AQLQ; and by mapping to the 3-level version of the EuroQol-5 Dimension (EQ-5D-3L) from AQLQ. The AQL-5D is derived from the AQLQ, a disease-specific questionnaire, and can be used in economic evaluation. It was decided to also map to EQ-5D-3L since data derived using the EQ-5D-3L is generally preferred by health technology assessment agencies when undertaking economic evaluation. The two questionnaires use different value sets to calculate the utility data, which results in similar, but not identical values.

The mapping from AQLQ to EQ-5D-3L and AQL-5D was done using previously developed algorithms [26, 27]. The mapping produced utility values for each patient at each scheduled and unscheduled visit in the trial. These utilities were entered into a mixed effects ML regression analysis, which estimated the predicted utility for well controlled asthma, and the predicted disutility of moving from well controlled asthma to the four health states of

---

**Fig. 2** Overview of analysis conducted on the MT-04 trial data

**ACQ data** (at each visit)

- Mapped to

**GINA control status**

**Utility measures** (EQ-5D and AQL-5D)

- Utility data by health state for EQ-5D and AQL-5D
  - Well controlled asthma
  - Partially controlled asthma
  - Uncontrolled asthma
  - Moderate exacerbation
  - Severe exacerbation

**Trial definition of exacerbations** (see Box 1)
partially controlled asthma, uncontrolled asthma, moderate exacerbation and severe exacerbation’ (Fig. 2). The model of estimated EQ-5D-3L and AQL-5D can be seen in Supplement 1.

**Results**

**MT-04 patient details and asthma control**

Seven hundred forty-two patients completed the trial and were included in the full analysis set [22]. Four hundred eighty-five patients received the active treatment (237 6 SQ-HDM SLIT, 248 12 SQ-HDM SLIT) and 257 received a placebo. The patient baseline characteristics and patient discontinuations are reported elsewhere [22]. At randomisation the percentage of patients reported to have partly controlled asthma was similar in the two groups (active treatment: 71%; placebo: 72%).

**Duration of exacerbations**

Two hundred four patients experienced a moderate or a severe exacerbation during period 3 of the trial. E-diary data demonstrated that moderate and severe exacerbations involved statistically significant reductions in lung function (morning and evening) compared to the average constant peak expiratory flow (PEF) observed for patients who did not experience exacerbations (Fig. 3). For both moderate and severe exacerbations lung function reduction occurred for about 28 days and started to decrease approximately 14 days before an exacerbation followed by a gradual return to baseline over 14 days.

During both moderate and severe exacerbations, asthma symptoms, SABA use, and the frequency of nocturnal awakening all increased, starting 10–14 days before an exacerbation and returned to baseline within 10–28 days following the exacerbation (Fig. 3).

There was a statistically significant difference in symptoms between those with moderate or severe exacerbations compared to patients who did not experience exacerbations (p < 0.05).

**Utilities**

Utility values were derived for five asthma health states: well controlled, partially controlled, uncontrolled, moderate and severe exacerbation (Table 2).

The utility values for the ‘well controlled asthma’ health state were 0.923 (standard error (SE): 0.000716) for EQ-5D-3L and 0.985 (SE: 0.000844) for AQL-5D. The disutility values of having ‘partially controlled asthma’ compared to ‘well controlled asthma’, for each of the four cut-offs for the number of days, ranged from −0.0251 to −0.0252 for EQ-5D-3L and −0.0362 to −0.0364 for AQL-5D; and of having ‘uncontrolled asthma’ compared to ‘well controlled asthma’, ranged from −0.0632 to −0.0634 for EQ-5D-3L and −0.0866 to −0.0873 for AQL-5D.

Compared to ‘well controlled asthma’, the data for disutility of having a ‘moderate exacerbation’ ranged from −0.0834 to −0.0876 for EQ-5D-3L and −0.114 to −0.121 for AQL-5D; and of having a ‘severe exacerbation’ ranged from −0.115 to −0.163 for EQ-5D-3L and −0.153 to −0.217 for AQL-5D. Compared to ‘well controlled asthma’, the disutility values of having exacerbations were more than having partially controlled or uncontrolled asthma.

**Discussion**

This post-hoc analysis demonstrates that the impact of moderate and severe exacerbations in HDM AA extends long before and after the peak exacerbation event. Symptoms and medication use increase up to 14 days prior to the onset of an exacerbation. After the exacerbation, patients’ symptoms and medication use returns to baseline more slowly than reported in the literature [28]. For example, lung function took 14 days on average to return to baseline and patients’ asthma symptoms, SABA use and frequency of nocturnal awakening took between 10 and 28 days to return to baseline. This demonstrates that PEF and symptomatic measures describe different aspects of asthma control and might not be useful as proxies. Patients’ symptoms and medication use are also affected for 14 days after an exacerbation.

Similarly, the impact of exacerbations on HRQoL (utility) continues long after the occurrence of the exacerbations. Not only do utility scores exhibit change over several weeks around an exacerbation, but the size of the change is also important. These analyses showed that AA patients experience a reduction in HRQoL (disutility) that is greater than 0.05 during moderate (range −0.0834 to −0.121) and severe (range −0.115 to −0.217) exacerbations, as well as during times of uncontrolled asthma (range −0.0632 to −0.0873). The disutilities obtained by mapping to AQL-5D were larger than those obtained by mapping to EQ-5D. This may be due to the AQL-5D being a disease-specific questionnaire and is therefore more sensitive to the impact on subjects’ HRQoL.

MT-04 demonstrated that time to a first moderate or severe exacerbation increases in patients who receive active treatment [22]. Prolonging the time to exacerbation means that patients experience a higher HRQoL for a longer period of time and experience fewer symptoms and require less reliever medication. The data for MT-04 are consistent with data reported by Briggs [29] who incorporated AQLQ data (from the Gaining Optimal Asthma control (GOAL) study mapped to utility) to analyse the cost-effectiveness of asthma control treatment. Briggs calculated a disutility of −0.216 for exacerbations, but did not distinguish between moderate and severe. The definition of an exacerbation used in Briggs was similar to that for ‘severe’ exacerbation used in MT-04.
The largest disutility value calculated for MT-04 was $-0.217$ for a severe exacerbation. Lloyd [12] reported that EQ-5D was significantly worse for asthma patients experiencing exacerbations. They reported the utility of patients not in exacerbation was $0.89$, the utility of patients in exacerbation without steroids was $0.57$ and the utility of patients in exacerbation and hospitalised was $0.33$. Although the patients in this trial had more severe asthma than those in MT-04, the impact of exacerbations on HRQoL in Lloyd et al. is similarly apparent.

The effect of asthma exacerbations on utilities is greater in MT-04 than the disutilities for acute events in other diseases. Harris [30] reported that non-severe hypoglycaemia resulted in HRQoL decreases of between $-0.0056$ and $-0.0076$ and decreases for severe hypoglycaemia between $-0.0592$ and $-0.0616$. Davies [31] reported disutilities for two acute events of $-0.06$ for myocardial infarction and $-0.05$ for unstable angina. This analysis of MT-04 has shown that the effects of asthma exacerbations can be experienced for weeks before and after the event, whereas events in other disease areas can be much shorter. For example, prolonged angina lasts more than 20 min [32], typical chest pain in acute myocardial infarction may last between 30 and 60 min [33] and the duration of a hypoglycaemic episode may be minutes or hours [34].

A limitation of this study is that the definition of a moderate asthma exacerbation was used for the first time in the MT-04 trial and might have limited usability in clinical practice. The number of exacerbations may be considered small. This is a result of the trial design, where patients were able to discontinue after the experience of the first asthma exacerbation or continue on an increased ICS dose. This approach may be the reason that few patients experienced more than one exacerbation. For the current analysis, this means that the impact of repeated exacerbations on HRQoL could not be measured. A further limitation was that the analyses did not control for the timing between exacerbation occurrence and AQLQ assessment. Finally, most of the trial analyses described in this paper were post-hoc.

Future research in AIT should carefully consider the method by which HRQoL is measured during exacerbations so that the impact of exacerbations can be measured accurately.
captured accurately in terms of intensity as well as duration. Future modelling could analyse the relationship between utility and duration of exacerbation. HRQoL should also be measured in an AIT trial without ICS reduction and a primary endpoint which assesses the frequency of exacerbations rather than time to exacerbation. This would enable assessment of the impact on HRQoL and the health economic impact of repeated exacerbations. Future asthma research should seek to capture data on moderate exacerbations, to increase our understanding of their effects compared to severe exacerbations.

Conclusions
In conclusion, moderate and severe HDM AA exacerbations lead to increases in symptoms and medication use as well as reduction in lung function over a longer time period than previously appreciated: up to 14 days prior to an exacerbation and up to 28 days after [28]. Exacerbations, both moderate and severe, lead to a decrease in HRQoL. Severe exacerbations lead to significantly more variation in lung function, asthma symptoms, SABA use and frequency of nocturnal awakening than moderate exacerbations.

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s41687-020-00274-x.

Additional file 1: Table S1. Models of estimated EQ-SD-3L and AQL-5D (All data observed within 7, 14, 21 and 28 days from a reported asthma exacerbation).

Abbreviations
AA: Allergic Asthma; ACQ: Asthma Control Questionnaire; AIT: Allergy Immunotherapy; AQL-5D: Asthma Quality of Life Questionnaire – 5 Dimensions; AQLQ: Asthma Quality of Life Questionnaire; ATS: American Thoracic Society; EQ-SD: EuroQol 5 Dimensions; ERS: European Respiratory Society; FEV1: Forced Expiratory Volume in 1 Second; GINA: Global Initiative for Asthma; GOAL: Gaining Optimal Asthma Control; HDM: House Dust Mite; HDM AA: House Dust Mite induced Allergic Asthma; HRQoL: Health-related Quality of Life; ICS: Inhaled Corticosteroid; PEF: Peak Expiratory Flow; SABA: Short-Acting Beta Agonists; SLIT: Sublingual Immunotherapy; TTO: Time Trade-Off
Acknowledgements
The authors thank Julie Gnanville and Chris Bartlett for editorial assistance with the manuscript. Both are employees of York Health Economics Consortium, York, UK.

Authors’ contributions
AB provided statistical expertise selecting the methodology of the post-hoc analyses and interpretation of data. CV was principal investigator of the MT-04 trial and contributed to the interpretation of the post-hoc analyses. SN gave clinical input to the post-hoc analyses and interpretation of results. EH and SB gave methodological input to the post-hoc analyses and interpretation of results. All authors provided critical review of the manuscript and approved submission for publication.

Funding
This MT-04 trial and these post-hoc analyses were both funded by ALK Abelló.

Availability of data and materials
The datasets used and analysed during the current study are available from the corresponding author on reasonable request.

Ethics approval and consent to participate
This study was a post-hoc analysis of data collected in the MT-04 trial. The relevant independent ethics committee and institutional review board approved the trial protocol and amendments, and the trial followed the principles of the Helsinki Declaration.

Consent for publication
Not applicable.

Competing interests
AB and SN report personal fees from ALK, during the conduct of the study. EH and SB are employees at ALK-Abelló A/S. JCV is an employee of the University of York and has lectured for and received honoraria from: ALK-Abelló, Allergopharma, AstraZeneca, Avantor, Bayer, Bercard, Bionorica, Boehringer-Ingehelm, Cipla, Chiesi, Essex/Scherling-Plough, GSK, Janssen-Cilag, Leti, MEDA, Merck/MUSD, Mundipharma, Novartis, Nycomed/Altana, Pfizer, Revotar, Sandoz-Hexal, Stallergens, TEVA, UCB/Schwarz-Pharma, Zydox/Cadila and possibly others and has participated in Advisory Boards of ALK-Abelló, Allergopharma, Avantor, Boehringer-Ingehelm, Cipla, Chiesi, Essex/Scherling-Plough, GSK, Janssen-Cilag, Leti, MEDA, Merck/MUSD, Mundipharma, Novartis, Paul-Ehrlich-Institute, Regeneron, Revotar, Roche, Sanofi-Aventis, Sandoz-Hexal, TEVA, UCB/Schwarz-Pharma and possibly others and has received funding for research from Deutsche Forschungsgemeinschaft, Land Mecklenburg-Vorpommern, GSK, MSD.

Author details
1Department of Health Services Research & Policy, London School of Hygiene & Tropical Medicine, London, England. 2Department of Allergy, Cambridge University Hospitals NHS Foundation Trust, Cambridge, England. 3ALK-Abelló A/S, Bøge Allé 1, DK-2970 Hørsholm, Denmark. 4Department of Pulmonology/Intensive Care Medicine, University of Rostock, Rostock, Germany.

Received: 8 June 2020 Accepted: 11 December 2020
Published online: 12 January 2021

References
1. Medical Review (2015). Allergens and allergic asthma. Asthma and allergy Foundation of America [cited Feb 05 2018]. Available from: http://www.aafa.org/page/allergic-asthma.aspx.
2. Nathan, R. A. (2007). The burden of allergic rhinitis. Allergy and Asthma Proceedings, 28(1), 3–9.
3. Schatz, M. (2007). A survey of the burden of allergic rhinitis in the USA. Allergy, 62(Suppl 85), 9–16.
4. Sadatsafavi, M., & Fitzgerald, J. M. (2014). Economic burden of asthma [cited Feb 22nd 2018]. Available from: http://www.globalasthmareport.org/burden/economic.php.
5. Ivanova, J. I., Bergman, R., Bimbaum, H. G., Colice, G. L., Silverman, R. A., & McLaurin, K. (2012). Effect of asthma exacerbations on health care costs among asthmatic patients with moderate and severe persistent asthma. The Journal of Allergy and Clinical Immunology, 129(5), 1229–1235.
6. Global Initiative for Asthma, National Heart Lung and Blood Institute (2002). Global strategy for asthma management and prevention. (NIH publication no. 02–3659). Bethesda National Institutes of Health National Heart Lung and Blood Institute.
7. Platts-Mills, T. A., Ward, G. W., Sporik, R., Gelber, L. E., Chapman, M. D., & Heymam, P. W. (1991). Epidemiology of the relationship between exposure to indoor allergens and asthma. International Archives of Allergy and Applied Immunology, 94(1–4), 339–345.
8. Zureik, M., Neukirch, C., Leynaert, B., Liard, R., Bousquet, J., & Neukirch, F. (2002). Sensitisation to airborne mites and severity of asthma. Cross sectional study from European Community respiratory health survey. BMJ, 325(7361), 411–414.
9. Petersen, K. D., Kronborg, C., Gyd-Hansen, D., Dahl, R., Larsen, J. N., & Lowenstein, H. (2008). Quality of life in rhinoconjunctivitis assessed with generic and disease-specific questionnaires. Allergy, 63(3), 284–291.
10. Valovirta, E., Myrseth, S. E., & Palkonen, S. (2008). The voice of the patients: Allergic rhinitis is not a trivial disease. Current Opinion in Allergy and Clinical Immunology, 8(1), 1–2.
11. Global Initiative for Asthma (2020). Global strategy for asthma management and prevention (2020 update) Available from: https://ginasthma.org/wp-content/uploads/2020/04/GINA-2020-full-report_final_wms.pdf.
12. Lloyd, A. Price, D., & Brown, R. (2007). The impact of asthma exacerbations on health-related quality of life in moderate to severe asthma patients in the UK. Primary Care Respiratory Journal, 16(1), 22–27.
13. Reddel, H. K., Taylor, D. R., Bateman, E. D., Boulet, L. P., Boushey, H. A., Busse, W. W., et al. (2009). An official American Thoracic Society/European Respiratory Society statement: Asthma control and exacerbations: Standardizing endpoints for clinical asthma trials and clinical practice. American Journal of Respiratory and Critical Care Medicine, 180(1), 59–99.
14. Mroczek, B., Kurpas, D., Urban, M., Skizko, Z., & Grabdski, T. (2015). The influence of asthma exacerbations on health-related quality of life. Advances in Experimental Medicine and Biology, 873, 65–77.
15. Bateman, E. D., Bouhey, H. A., Boushey, J., Busse, W. W., Clark, T. J., Pauwels, R. A., et al. (2004). Can guideline-defined asthma control be achieved? The gaining optimal asthma Control study. American Journal of Respiratory and Critical Care Medicine, 170(8), 836–844.
16. Pauwels, R. A., Pedersen, S., Busse, W. W., Tan, W. C., Chen, Y. Z., Ohlsson, S. V., et al. (2003). Early intervention with budesonide in mild persistent asthma: A randomised, double-blind trial. Lancet, 361(9363), 1071–1076.
17. Nasser, S. (2016). An imperfect “PAST” lessons learned from the National Review of asthma deaths (NRAD) UK. Respiratory Research, 17(1), 87.
18. Reddel, H., Ware, S., Marks, G., Salome, C., Jenkins, C., & Woolcock, A. (1999). Differences between asthma exacerbations and poor asthma control. Lancet, 353(9150), 364–369.
19. Global Initiative for Asthma (2008). Global strategy for asthma management and prevention. Madrid Del Rey: Medical Communications Resources.
20. Des Roches, A., Paradis, L., Menardo, J. L., Bouges, S., Daures, J. P., & Pauwels, J. (1997). Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. VI. Specific immunotherapy prevents the onset of new sensitizations in children. The Journal of Allergy and Clinical Immunology, 99(4), 453–459.
21. Global Initiative for Asthma (2017). Global strategy for asthma management and prevention (2017 update). Global Initiative for Asthma Available from: http://ginasthma.org/2017-gina-report-global-strategy-for-asthma-management-and-prevention/.
22. Vichow, J., Backer, V., Kuna, P., et al. (2016). Efficacy of a house dust mite sublingual allergen immunotherapy tablet in adults with allergic asthma: A randomized clinical trial. JAMA, 315(16), 1715–1725.
23. Blais, M., Metzner, E. O., Murphy, K., Nathan, R., & Stoloff, S. (2011). Duration of asthma episodes reported by patients in the asthma insight and management survey. Annals of Allergy, Asthma & Immunology, 107, A40–A41.
24. Vichow, J. C., Backer, V., de Blay, F., Kuna, P., Ljorring, C., Prieto, J. L., et al. (2015). Defining moderate asthma exacerbations in clinical trials based on ATS/ERS joint statement. Respiratory Medicine, 109(5), 547–556.
25. Vichow, J., Bufe, A., Seitzberg, D., & Bateman, E. (2011). Global initiative for asthma classification of asthma control derived from the asthma control questionnaire data. The Journal of Allergy and Clinical Immunology, 66, 149.
26. Tschiriya, A., Brazier, J., McColl, E., & Parkin, D. (2002). Deriving preference-based single indices from non-preference based condition-specific instruments:
Converting AQLQ into EQ 5D indices. Sheffield: University of Sheffield School of Health and Related Research Available from: http://eprints.whiterose.ac.uk/10952/1/HEDS_DP_02-01.pdf.

27. Yang, Y., Brazier, J. E., Tsuchiya, A., & Young, T. A. (2011). Estimating a preference-based index for a 5-dimensional health state classification for asthma derived from the asthma quality of life questionnaire. Medical Decision Making, 31(2), 281–291.

28. Tattersfield, A. E., Postma, D. S., Barnes, P. J., Svensson, K., Bauer, C. A., O'Byrne, P. M., et al. (1999). Exacerbations of asthma: A descriptive study of 425 severe exacerbations. The FACET international study group. American Journal of Respiratory and Critical Care Medicine, 160(2), 594–599.

29. Briggs, A. H., Bousquet, J., Wallace, M. V., Busse, W. W., Clark, T. J. H., Pedersen, S. E., et al. (2006). Cost-effectiveness of asthma control: An economic appraisal of the GOAL study. Allergy, 61(5), 531–536.

30. Harris, S., Mandani, M., Galbo-Jørgensen, C. B., Bøgelund, M., Gundgaard, J., & Groleau, D. (2014). The effect of hypoglycemia on health-related quality of life: Canadian results from a multinational time trade-off survey. Canadian Journal of Diabetes, 38(1), 45–52.

31. Davies, E. W., Matza, L. S., Worth, G., Feeny, D. H., Kostelec, J., Soroka, S., et al. (2015). Health state utilities associated with major clinical events in the context of secondary hyperparathyroidism and chronic kidney disease requiring dialysis. Health and Quality of Life Outcomes, 13, 90.

32. Yusuf, S. W. (2018). Unstable angina - symptoms, diagnosis and treatment [cited January 18th 2018]. Available from: https://bestpractice.bmj.com/topics/en-gb/149.

33. Maziar Zafari, A., & Abdou, M. H. (2018). Myocardial infarction [cited January 18th 2018]. Available from: https://emedicine.medscape.com/article/155919-overview.

34. Mayo Clinic (2018). Hypoglycemia [cited January 18th 2018]. Available from: https://www.mayoclinic.org/diseases-conditions/hypoglycemia/symptoms-causes/syc-20373685.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.